To Transplant or Not To Transplant in Multiple Myeloma
Clinical Advances in Hematology & Oncology [button style=”download” link=”https://www.hematologyandoncology.net/files/2014/05/ho0514_counter1.pdf” color=”teal”]Download Paper[/button] Authors: James R. Berenson,…
Replacement of Bortezomib with Carfilzomib for Multiple Myeloma Patients Progressing from Bortezomib Combination Therapy
J R Berenson1,2,3, J D Hilger2, O Yellin2, R Dichmann4, D Patel-Donnelly5, R V Boccia6, A Bessudo7, L Stampleman8, D Gravenor9, S Eshaghian10, Y Nassir11, R…
A Phase 2 Study of Accelerated Elotuzumab Infusion, over Less than 1 Hour, in Combination with Lenalidomide and Dexamethasone, in Patients with Multiple Myeloma
Abstract Elotuzumab, an immunostimulatory SLAMF7-targeting monoclonal antibody, induces myeloma cell death with minimal effects on…